Background: This study examined the relationships of depressive symptoms and social anxiety with perceived neck function in patients treated for head and neck cancer.
multimodality therapy often results in functional loss, including difficulties with speech, eating, sight, and smell, as well as musculoskeletal impairment involving the neck, shoulders, and jaw. 3 Because of the highly visible location and structures affected, the disease and its treatment are both psychologically and physically intrusive. 4 Recovery from head and neck cancer and its treatment is an extended process. In particular, morbidity may persist for months or years after the completion of treatment, impairing survivors' ability to complete activities of daily living and decreasing their quality of life. 5 Lymphedema and fibrosis are ubiquitous in this population and are associated with significant functional deficits. 6, 7 For example, individuals who are not able to drive a car due to limited neck mobility may become socially isolated from precancer social networks.
Other individuals who have difficulty eating may find it awkward to socialize with their friends and family over meals. Changes in a survivor's voice make it difficult to communicate clearly. Survivors of head and neck cancer with lymphedema are more likely to report altered sensation symptoms, including numbness, heaviness, warmth, swelling, problems breathing and swallowing, and increased pain in the head and neck area as opposed to those without lymphedema. 8 Decline in general physical function has been associated with increased psychological distress in patients with head and neck cancer. 9, 10 Specifically, survivors may experience social anxiety, making every-day interactions with family, friends, and others problematic. 10 However, no known studies have examined the association among perceived neck functional loss, depressive symptoms, and social anxiety. It is important for clinicians to anticipate which patients may experience depressive symptoms and social anxiety along with functional loss so early intervention can be initiated. Therefore, the purpose of this study was to examine the relationship between depressive symptoms and social anxiety with perceived neck-related functional loss in patients with head and neck cancer.
| M ATE RI ALS AN D ME THO DS

| Sample
Five hundred three patients with newly diagnosed head and neck cancer patients were screened over a 25-month period at Vanderbilt-Ingram Cancer Center (VICC) to participate in a study that had as its primary aim to examine the prevalence and nature of late-effect internal, external, and combined lymphedema and fibrosis. Of the 149 patients who were approached by study staff to discuss participation, 100 gave informed consent. Depressive symptoms and social anxiety were captured as part of the study. Eligibility criteria included: (1) newly diagnosed, histologically proven head and neck cancer (carcinoma of the oral cavity, larynx, pharynx, paranasal sinuses and nasal cavity, or saliva glands); (2) stage II disease or greater; (3) age 21 years or older; (4) willing and able to undergo baseline and follow-up assessment at VICC; and (5) able to speak and understand English. Exclusion criteria for continuation in the study included: (1) documented cognitive impairment that would preclude the ability to provide informed consent; (2) unwilling to undergo routine follow-up at VICC; and (3) recurrent cancer. No restrictions were placed on the type of treatment participants received for inclusion in the study. Seventeen patients were lost to follow-up or were withdrawn before the initial 3-month follow-up assessment. Eighty-four were in the study 3 months posttreatment, 83 of which completed the first posttreatment follow-up and, therefore, comprised the study sample.
| Procedure
The study was approved by the Vanderbilt Institutional Review Board and the VICC Scientific Review Committee. Participants provided written informed consent before study entry. They were asked to complete study measures at baseline (before radiation and/or chemotherapy), at the end of head and neck cancer treatment, every 6 weeks thereafter until 48 weeks after the end of head and neck cancer treatment, and at 15 and 18 months after the end of head and neck cancer treatment for a total of 11 assessment time points.
| Measures
Demographic and clinical information, disease and treatment information, head and neck-related function, depressive symptoms, and social anxiety were examined in this study. Musculoskeletal impairment related to neck dysfunction was measured using the Neck Disability Index (NDI). The NDI is a 10-item instrument that taps components of daily life that may be affected by neck pain and dysfunction. 11 Items include pain, personal care, lifting, reaching, headache, concentration, work, driving, sleeping, and recreation. A Gutman-style response format is used, with 6 possible responses reflecting increasing degrees of disability. Items are summed to provide a total score. 11 Scores of 10%-28%
are considered mild disability, 30%-48% are considered moderate disability, 50%-68% are considered severe disability, and 72% or more are considered complete disability.
11
Depressive symptoms were measured using the Center for Epidemiological Studies Depression (CES-D) scale. The CES-D is a 20-item instrument designed to measure the current level of depressive symptomatology, with emphasis on the affective component, depressed mood. 12 The symptoms are among those on which a diagnosis of clinical depression is based but which may also accompany other diagnoses to some degree. Each item is scored 0 5 "less than one day," 1 5 "some or a little of the time (1-2 days)," 2 5 "occasionally or a moderate amount of time (3-4 days)," or 3 5 "most or all of the time (5-7 days)." Four items are reverse scored. A score of >16 is used to identify individuals who may be at risk for clinical depression. 13 The study participant's medical oncologist was immediately notified each time a participant scored 16 or greater on the CES-D. Social anxiety was measured using the Liebowitz Social Anxiety Scale (LSAS).
14 This generic scale contains 24
items that assess social interaction and performance situations an individual may face. Each situation is rated on a 4-part scale (0 5 none to 3 5 severe) for both fear and avoidance. Some example situations include going to a party, meeting strangers, and talking with people you do not know very well. Originally designed as a clinician-administered scale, it has been tested as a self-report instrument with adequate internal consistency. Both the clinician administered and self-report versions have been found to be internally consistent (alpha 5 0.96). 15 
| Data analysis
The IBM SPSS version 24 was used for data analysis. Due to the positive skewness of the data distributions, median and interquartile range (IQR) values were used to describe primary study variables. Handling of missing data in the measures are described elsewhere. 6 To maximize the number of assessments within each of the critical posttreatment time periods and use cases with randomly missing assessments within those periods, the assessment periods were collapsed into those between 1 and 6 weeks posttreatment (designated end of treatment), 12 to 24 weeks posttreatment (3-6 months), 30 to 36 weeks posttreatment (approximately 9 months), 42 to 48 weeks posttreatment (approximately 12 months), and 60 to 72 weeks posttreatment (>12 months). If more than 1 score for the NDI, CES-D, or LSAS was available during any of these periods, the maximum score was used for the analyses reported here. Because the primary focus of this secondary analysis was on the longitudinal patterns of neck-related function (NDI trajectories) and the associations of specific longitudinal patterns (trajectories) of depressive symptoms and social anxiety with those NDI trajectories in patients with head and neck cancer posttreatment, group-based trajectory modeling (SAS PROC TRAJ) was determined to provide the optional approach. This approach was used to generate "clusters" of patients with similar baseline and trajectories of neck-related function (NDI) for the 12 to 18 months posttreatment for head and neck cancer. The Akaike Information Criteria and Bayesian Information Criteria statistical indices were used to determine the optimal shape (linear, quadratic, etc) and number of clusters in the longitudinal data. A separate groupbased trajectory modeling analysis was used to generate clusters of patients with similar trajectories of depressive symptoms (CES-D) and social anxiety (LSAS). For each of the trajectory modeling analysis, baseline, and at least 1 posttreatment assessment value were required for inclusion in the analysis (number of participants 5 83). To verify the reliability of the findings, a second analysis of each measure was conducted using only the subsample of patients who had an assessment at least 1-year posttreatment (N 5 62). The shape and number of clusters were replicated in each result; therefore, the larger sample findings are reported here. Descriptive statistical and graphical summaries were used to explore the relationships among the trajectories of NDI, CES-D, and LSAS scores. Likelihood chi-square tests were used to test the associations of the NDI trajectories with those observed for CES-D and LSAS. Linear mixed-level analysis (between NDI trajectory groups, within-subject patterns of CES-D, and LSAS scores) were used to test for differences in the patterns of CES-D and LSAS scores among the NDI trajectory groups (clusters). Statistically significant main or interaction effects from this analysis would suggest an association of the NDI trajectory pattern with the longitudinal pattern of CES-D and/or LSAS scores. Consistent findings from the Likelihood chi-square test associations of the "groups" formed by the trajectory modeling and the findings from the linear mixed modeling approach would provide convergent validation for the associations between the 2 phenomena.
To explore possible associations of demographic and treatment characteristics with the derived NDI trajectories, tests of those variables (eg, age, sex, t test, percutaneous endoscopic gastrostomy [PEG] tube) were conducted using chi-square tests of independence (nominal characteristics) or Kruskal-Wallis tests (ordinal, continuous characteristics). An alpha level of 0.05 was used for determining statistical significance. If post hoc tests were required, a Bonferroni corrected alpha level was used.
| R ES ULT S 3.1 | Sample characteristics
The details of the screening, recruitment, and enrollment data for the primary study are described by Ridner et al 6 
in 2016.
Of the 100 participants recruited for the primary study, 83 were ultimately included in study analyses. Of the 17 patients lost to follow-up, 4 did not complete the baseline assessments. The remaining 13 participants lost to follow-up were more likely to be single or widowed, have stage IV disease, received induction chemotherapy, and have metastatic disease. 6 The majority of participants were white (n 5 75;
90.4%), men (n 5 60; 72.3%), and middle-aged (mean 57.8 years). Most participants were married or living with a partner (n 5 65; 78.3%) and had a history of tobacco use (n 5 61; 73.5%). The most common tumor location was the oropharynx (n 5 36; 43.4%). Although 1 participant was initially reported to have stage II disease, it was later reclassified as stage I disease after enrollment in the study. The majority of participants received concurrent chemoradiation treatment for their disease (n 5 81; 97.6%), and slightly less than one third of participants had surgery in addition to concurrent chemoradiation treatment (n 5 24; 29. 
| Neck Disability Index trajectories
The optimal group-based trajectory model in terms of best fit using the Bayesian Information Criteria and Akaike Information Criteria resulted in 3 clusters of longitudinal patterns in NDI, which is illustrated in Figure 1 . More than a third of the participants (N 5 30; 36.1%) were experiencing notable levels of neck disability before treatment. The median level increased during treatment and generally fluctuated around the initial level throughout the study period. There was no detectable decrease in severity. The smallest cluster of participants (N 5 15; 18.1%) demonstrated minimal disability before treatment with some increasing levels at the end of treatment with diminishment to very few limitations by 18 weeks posttreatment and subsequently. The remaining approximately 46% of the participants (N 5 38; 45.8%) demonstrated similar levels of disability to the prior cluster before head and neck cancer treatment, however, they experienced considerably higher levels of neck disability at the end of treatment and the limitations did not diminish as much posttreatment. Summaries of the demographic and clinical characteristics of the NDI trajectory groups are shown in Table 1 . Current or past medical problems and the need for a PEG tube demonstrated the strongest associations with the NDI trajectory patterns. Those with current or past medical problems and those in need of a PEG tube were more likely to demonstrate an NDI pattern consistent with 1 of the more severe trajectories (P < .05; see Table 1 ). There were also statistically significant differences among the trajectory groups in terms of education and sex (P < .05). Post hoc pairwise tests among the 3 groups revealed that, compared to the severe-to-moderate trajectory group, the moderate-tomild trajectory group had a higher median education (14 vs 12 years) and a higher percentage of men (84.2% vs 56.7%; P < .05; see Table 1 ).
| Associations of Neck Disability Index trajectories with depressive and social anxiety symptoms
Illustrations of the longitudinal clusters of participants derived from the CES-D and the LSAS scores are shown in Figure 2 . Notably similar to the number of clusters observed for the NDI scores, 3 to 4 clusters were observed for those measures with similar proportions in the severity levels (approximately 15% minimal, 45%-55% moderate-to-mild, and approximately 35% severe-to-moderate). Statistically significant associations were found between membership in the NDI trajectories and membership in the longitudinal patterns of CES-D and LSAS (Cramer's V, CES-D: 0.55, P < .001; LSAS Total: 0.35, P 5 .002; LSAS Fear: 0.35, P 5 .002; and LSAS Avoidance: 0.35, P 5 .003). In other words, 77% (N 5 23 of 30) of the participants who manifested the severe-to-moderate NDI longitudinal pattern, they also manifested the CES-D pattern characterized by the highest levels of depressive symptoms. Slightly more than half of those in the severe-to-moderate NDI longitudinal cluster (N 5 16 of 30; 53.3%) also were members of the LSAS cluster with the highest levels of social anxiety. Consistent with those findings, statistically significant differences in the patterns of prior and posttreatment symptoms of depression and social anxiety were revealed among the 3 NDI trajectory groups. The CES-D and LSAS scores for each of the NDI groups are summarized in Table  2 . Mixed-effects generalized linear model (GLM) revealed not only a main effect of NDI group on CES-D (F (df 5 2) 5 243.91, P < .001) but also a statistically significant interaction effect of NDI group and time of assessment (F (df 5 22) 5 2.40, P 5 .001). Post hoc contrasts revealed that before and through 6 months posttreatment, the severe-to-moderate neck disability group had statistically significantly higher levels of depressive symptoms than did the other 2 trajectory groups (all Bonferroni P < .01). Rates of CES-D scores in the clinical range ( 19) in the severe-to-moderate disability group were 53.3% at baseline (N 5 16 of 30) and >70% at end of treatment and 6 months posttreatment (N 5 23 and 21). Respective rates for the other 2 trajectories were <25% at baseline, increased to 30%-35% at end of treatment, and reduced to <20% at 6 months posttreatment. The groups defined by NDI trajectories further delineated themselves in terms of depressive symptoms a year and more posttreatment. The minimal disability trajectory group had lower CES-D scores than did the trajectory with moderate-to-mild disability, which had lower scores than did the severe-tomoderate trajectory group (all Bonferroni P < .01). Rates of clinically significant depressive symptoms remained >50% in the severe-to-moderate trajectory group, whereas rates in the other trajectory groups diminished to approximately <10%.
Although no statistically significant interaction effects were observed on the LSAS scores, statistically significant main effects of NDI trajectory were observed (Total: F (df 5 2) 5 84.93, P < .001; Fear: F (df 5 2) 5 85.50, P < .001; and Avoidance: F (df 5 2) 5 84.28, P < .001). Throughout the longitudinal course of the study, the participants with an NDI trajectory characterized by severe-to-moderate disability had higher levels of social anxiety than did those with the moderate-to-mild levels of disability who in turn had higher levels of social anxiety than did those with minimal disability levels (all Bonferroni P < .001).
| D IS C US S I ON
Our sample was reflective of the age, sex, and tumor pathology of individuals diagnosed with head and neck cancer. 16 Although the majority of individuals in the greater population are diagnosed with oral cavity cancer, the largest number of individuals in our study were diagnosed with oropharyngeal cancer. This may be due to the increase in HPV rather than smoking and drinking as a causative factor for oropharyngeal cancer, particularly among younger individuals. High symptom burden after treatment for head and neck cancer has been well documented. 7, 17, 18 Our findings indicate that, after treatment for head and neck cancer, selfreported impaired neck-related function is not only associated with depressive symptoms and social anxiety but these issues also cluster into 1 of 3 distinct symptom trajectories. Only a small number of patients in our study experienced a symptom trajectory that could be characterized as minimal. More than a third of patients experienced a severe to moderate symptom trajectory. The most common symptom trajectory experienced by patients began with minimal symptom burden that escalated to a moderate level immediately after treatment and eventually declined. Symptom burden returned to a mild level but did not reach the level of minimal symptom burden over the subsequent 18 months. Impaired physical function and psychological distress are clearly intertwined for patients with head and neck cancer long after completing treatment. Our findings are supported by other studies examining diverse types of impaired physical function and psychological distress in this population. In a longitudinal study of 101 patients with head and neck cancer, a higher number of treatment-related physical symptoms predicted both depression and anxiety. 19 Another study of 280 patients diagnosed with head and neck cancer found that participants with speech and eating concerns reported the highest levels of body image disturbance compared with those without such concerns. 20 Of the known studies that examine postcancer treatment symptom trajectories, [21] [22] [23] [24] [25] [26] none have examined the trajectories of symptom clusters, including depressive symptoms, social anxiety, and perceived neck function in individuals with head and neck cancer.
| Strengths and limitations
A key strength of our study is that participants were largely reflective of the greater population of individuals with head and neck cancer. Another strength of our study is the longitudinal design that allowed us to identify symptom cluster trajectories; we followed patients from their time of diagnosis until 18 months after the end of treatment. Additionally, we used valid and reliable data collection tools. However, there were significant differences in participants who were lost to follow-up and those included in this analysis. Given that participants who were lost to follow-up were more likely to have a higher disease stage, induction chemotherapy, and metastatic disease, these participants likely experienced a higher symptom burden than the included participants.
Another limitation of this study is the possibility of survivor bias. Symptom burden, particularly in the moderate-tomild cluster trajectory, may have seemed to improve because the individuals with a greater symptom burden died at some point during the 18 months after the end of treatment. This supports the assertion that patients with head and neck cancer have a particularly high level of sustained symptom burden after treatment.
An additional limitation is the recruitment of participants at only one location in the United States. Although our recruitment was representative of individuals with head and neck cancer who seek care at our institution, African Americans, among other racial minorities, were underrepresented in our sample.
Because of the small trajectory groups, we were unable to adjust for possible demographic and clinical confounding variables. A larger study of this population is needed to facilitate this analysis.
Finally, other important limitations include limited statistical power based on the small sample sizes of the trajectory groups, exploratory analysis of secondary data, the inability to draw causal interferences from our data, the use of a generic social anxiety measure rather than a disease-specific measure, and the absence of information about patients with more limited disease.
| Implications
Given our findings, it is clear that patients with head and neck cancer must be holistically supported not only throughout treatment but also during the months after the end of treatment. This type of support must include mental health referrals as well as rehabilitation for functional impairments for affected patients. As our findings most likely underestimate the severity of symptom trajectories after treatment for head and neck cancer, it may be important for clinicians to identify individuals who are more likely to experience a more severe symptom trajectory. Interventions directed at individual treatable contributing factors may be of benefit for patients.
ORCID
Bethany Andrews Rhoten PhD, RN http://orcid.org/0000-0001-5274-2469
